DOCSLIB.ORG

Standard Times Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Standard Times Report Procedure Standard Time as of: 2021-04-06 Site: ACH Procedure Cat: 25 Selected Show Procedures: ALL Duration Procedure Cat / Standard Standard Site Proc Cd Fixed Standard Procedure Description Std BK Skin To Skin/ Total Setup/Teardown Proc Case ANA ACH Anesthesia Awake Intubation ANAWKINTB 10 10 / 10 = 20 30 ACH Anesthesia Block in PACU Pre OR Admission ANABKRR 10 5 / 10 = 15 25 ACH Anesthesia Blood Patch ANABLDPT 10 5 / 5 = 10 20 ACH Anesthesia Epidural Steroid+/-Analgesia Inject SS ANAEPINJ 10 10 / 10 = 20 30 ACH Anesthesia for XRay ANAXRAY 15 10 / 10 = 20 35 ACH Anesthesia Insert Long Line IV<1 Year ANALINE<1 25 15 / 15 = 30 55 ACH Anesthesia Insert Long Line IV>1 Year ANALINE>1 25 15 / 15 = 30 55 ACH Anesthesia Intubate Only OR ANAINTB / = ACH Anesthesia Intubate Only PACU ANAINTBRR 10 5 / 5 = 10 20 ACH Anesthesia Local+/-Regional Block State Type ANABKOR 30 15 / 15 = 30 60 ACH Anesthesia Post Op Readmit to PACU ANARADMRR 10 10 / 10 = 20 30 ACH Anesthesia Pseudocholinesterase Deficiency ANAPSURR 10 10 / 10 = 20 30 ACH Anesthesia Spinal Block ANASPBK 10 10 / 10 = 20 30 ACH Anesthesia Spine Facet Injection ANASPINJ 10 10 / 10 = 20 30 ACH Lumbar Puncture LUPUNC 10 25 / 15 = 40 50 CAR ACH Cardiac Catheterization & Balloon Angioplasty HRCARCBANG 90 20 / 20 = 40 130 ACH Cardiac Catheterization w Full Biopsy HRCARCBX 90 40 / 30 = 70 160 ACH Cardiac Catheterization w Partial Biopsy HRCARCBXP 40 20 / 20 = 40 80 ACH Cardiac Catheterization+/-Valvoplasty HRCARCVL 90 40 / 30 = 70 160 ACH Catheter Insertion Aphoresis CAINAPHP 20 15 / 10 = 25 45 ACH Heart Cardioversion HRCARDVS 15 20 / 15 = 35 50 ACH Heart Echocardiogram HRECHO 10 15 / 15 = 30 40 ACH Heart Echocardiogram Transesophageal HRECHOTE 15 10 / 10 = 20 35 ACH Heart Electrophysiology Study+/-Ablation HREPSA 30 15 / 15 = 30 60 ACH Heart ICD Extract Gen/Lead/Drain Infec+/-Temp Pace HRICEXDRI 120 45 / 30 = 75 195 ACH Heart ICD Insert Dual Chamber HRICDDC / = ACH Heart ICD Insert Dual Chamber Groin Approach HRICDDCGA / = ACH Heart ICD Insert Single Chamber HRICDSC / = ACH Heart ICD Insert Single Chamber Groin Approach HRICDSCGA / = ACH Heart ICD Insert Single Chamber Subcutaneous HRICDSCS / = ACH Heart ICD Insert w CRT HRICDCRT 120 60 / 30 = 90 210 ACH Heart ICD Insert w CRT Endocardial Transeptal HRICDCREND / = ACH Heart ICD Revision Generator Replace w Lead Insert HRICDRVGLD / = ACH Heart ICD Revision Generator Replacement HRICDRVG 45 45 / 10 = 55 100 ACH Heart ICD Revision Lead Extr+/-Replac+/-Gen Replac HRICDRVLG / = ACH Heart ICD Revision Lead Extrac Las wReplac for CRT HRICDRVLZC / = ACH Heart ICD Revision Lead Extract w Replace for CRT HRICDRVLXC 0 0 / 0 = 0 0 ACH Heart ICD Revision Lead Reposition HRICDRVL 45 15 / 10 = 25 70 ACH Heart ICD Revision LV Lead Upgrade CRT+/-Gen Chng HRICDRVCRT 0 0 / 0 = 0 0 ACH Heart Loop Recorder Insertion HRLOOPRI 20 20 / 15 = 35 55 ACH Heart Loop Recorder Removal HRLOOPRR 10 15 / 15 = 30 40 ACH Pacemaker Extraction Gen+/-Lead/Drain Infec+/-Temp HRPMEXDRI 0 0 / 0 = 0 0 ACH Pacemaker Insert Dual Chamber HRPMDC 70 35 / 20 = 55 125 ACH Pacemaker Insert Dual Chamber Groin Approach HRPMDCGA 0 0 / 0 = 0 0 Generated: 2021-04-06 11:02 Source: CAL ORIS medsurg Internal: proc_std_time 1 of 57 v.20191007 Disclaimer: This report is confidential. If received in error, notify AHS CAL ORIS via [email protected] Procedure Standard Time as of: 2021-04-06 Site: ACH Procedure Cat: 25 Selected Show Procedures: ALL Duration Procedure Cat / Standard Standard Site Proc Cd Fixed Standard Procedure Description Std BK Skin To Skin/ Total Setup/Teardown Proc Case ACH Pacemaker Insert Single Chamber HRPMSC 30 20 / 15 = 35 65 ACH Pacemaker Insert Single Chamber Groin Approach HRPMSCGA 0 0 / 0 = 0 0 ACH Pacemaker Insert Temporary HRPMINTP 45 35 / 20 = 55 100 ACH Pacemaker Insert w CRT HRPMCRT 45 15 / 10 = 25 70 ACH Pacemaker Insert w CRT Endocardial Transeptal HRPMCRTEND / = ACH Pacemaker Insert w His Bundle Pacing HRPMHISBP / = ACH Pacemaker Insert/Extraction Leadless HRPMLDLS / = ACH Pacemaker Revision Gen & Lead Upgrade to ICD HRPMRVICD 0 0 / 0 = 0 0 ACH Pacemaker Revision Gen & Lead Upgrade to ICD w CRT HRPMRVICDC 0 0 / 0 = 0 0 ACH Pacemaker Revision Generator Replace w Lead Insert HRPMRVGLEA / = ACH Pacemaker Revision Generator Replacement HRPMRVG 45 20 / 10 = 30 75 ACH Pacemaker Revision Lead Extr Laser wReplac for CRT HRPMRVLZC 0 0 / 0 = 0 0 ACH Pacemaker Revision Lead Extr+/-Replac+/-Gen Replac HRPMRVLG 45 15 / 10 = 25 70 ACH Pacemaker Revision Lead Extrac w Replace for CRT HRPMRVLCRT / = ACH Pacemaker Revision Lead Reposition HRPMRVL 0 0 / 0 = 0 0 ACH Pacemaker Revision LV LeadUpgrade forCRT+/-GenChg HRPMRVCRT 45 15 / 10 = 25 70 ACH Pacemaker/ICD Ext Laser Gen+/-Lead/Drain Inf+/-Tem HRPMICEXLZ 0 0 / 0 = 0 0 ACH Pacemaker/ICD Generator Removal HRPMICDGRE 45 15 / 10 = 25 70 ACH Pacemaker/ICD Pocket Rev+/-Hematoma/Capsu/Scar Rev HRPMICDPK 0 0 / 0 = 0 0 ACH Thoracotomy Heart Epicardial Lead Insertion THOEPCARLI / = COH ACH Aorta Ascend Arch Repl Endo Thor AA Stent+/-Hybrid HRAOARENDH / = ACH Aorta Coarctation w Graft HRCOAOGF / = ACH Aortic Coarctation Repair w/o Graft HRCOAORP / = ACH Aortic Root Dissection+/-Graft HRAORTGF / = ACH CABG Multiple Primary HRCABGMP / = ACH CABG Multiple Primary w Ablation RF HRCABGMPRF / = ACH CABG Multiple Redo HRCABGMR / = ACH CABG w Aortic Root Repair/Repl HRCABGARR / = ACH CABG w Aortic Root Repair/Repl Redo HRCABGARTR / = ACH CABG w Ascending Hemiarch Replace HRCABASHR / = ACH CABG w Valve Aortic Pulmonary Replace HRVLPUBY / = ACH CABG w Valve Repair/Repl Aortic HRCABGVA / = ACH CABG w Valve Repair/Repl Aortic Ablation RF HRCABGVARF / = ACH CABG w Valve Repair/Repl Aortic Mitral+/-Tric Redo HRCABGVRR / = ACH CABG w Valve Repair/Repl Aortic Mitral+/-Tricusp HRCABGVR / = ACH CABG w Valve Repair/Repl Aortic Redo HRCABGVARR / = ACH CABG w Valve Repair/Repl Mitral Ablation RF HRCABGVMRF / = ACH CABG w Valve Repair/Repl Mitral+/-Tricuspid HRCABGVMTR / = ACH CABG w Valve Repair/Repl Mitral+/-Tricuspid Redo HRCABGVMRR / = ACH Cardiopulmonary Bypass for Hypothermia HRBYHYPO / = ACH ECMO HRBYECMO / = ACH ECMO Line Repositioning HRBYECMOLR 50 10 / 10 = 20 70 ACH Heart Aneurysm Repair Bypass HRANRPBY / = ACH Heart Aortic Valve Implant Transcath Apical TAVI HRTAVIA / = ACH Heart Aortic Valve Implant Transcath Axillary TAVI HRTAVIAX / = Generated: 2021-04-06 11:02 Source: CAL ORIS medsurg Internal: proc_std_time 2 of 57 v.20191007 Disclaimer: This report is confidential. If received in error, notify AHS CAL ORIS via [email protected] Procedure Standard Time as of: 2021-04-06 Site: ACH Procedure Cat: 25 Selected Show Procedures: ALL Duration Procedure Cat / Standard Standard Site Proc Cd Fixed Standard Procedure Description Std BK Skin To Skin/ Total Setup/Teardown Proc Case ACH Heart Aortic Valve Implant Transcath Direct TAVI HRTAVID / = ACH Heart Aortic Valve Implant Transcath Femoral TAVI HRTAVIF / = ACH Heart Atrial Septal Defect Repair Bypass HRASDRPBY / = ACH Heart Heartmate Insertion HRHMTIN / = ACH Heart Impella Insertion HRIMPELLIN 0 0 / 0 = 0 0 ACH Heart Patent Ductus Arteriosis HRPDAN 90 30 / 20 = 50 140 ACH Heart Pericardial Centesis HRPRICNP 30 20 / 10 = 30 60 ACH Heart Tumour Excision w Bypass HRTUEX / = ACH Heart Ventral Septal Defect Repair Bypass HRVENSDRP / = ACH Heart Ventricular Assist Device Insertion HRVADIN / = ACH Heart Ventricular Assist Device Insertion MIS HRVADINMIS / = ACH Heart Ventricular Assist Device Removal HRVADRM / = ACH Post Open Heart Reopen Bleed HRPSOHRBL / = ACH Post Open Heart Reopen Low Flow HRPSOHRLF / = ACH Post Open Heart Sternal Closure HRPSOHSCL / = ACH Post Open Heart Sternal Plating HRPSOHSFX / = ACH Pulmonary Embolectomy w Bypass HRPUEMBBY / = ACH Sternal Debridement Post Open Heart STDBPSOH 45 60 / 20 = 80 125 ACH Sternal Rewiring STREWIR 30 30 / 30 = 60 90 ACH Sternal Wire Removal STWIRRM 15 30 / 10 = 40 55 ACH Sternotomy Pericardectomy STPCEC 120 75 / 30 = 105 225 ACH Thoracic Aneurysm Dissection+/-Replace w Bypass HRTXANBY / = ACH Thoracoabdominal Aortic Aneurysm Repair w Bypass HRTAARBY / = ACH Valve Aortic & Ascending Hemiarch Replacement HRVLASHEMR / = ACH Valve Aortic & Mitral Repair/ Replace+/-Tricuspid HRVLAMRRT / = ACH Valve Aortic & Mitral Repair/Replace+/-Tricus Redo HRVLAMRTR 195 75 / 30 = 105 300 ACH Valve Aortic Repl Ross Proc+/-Allograft+/-Homograf HRVLARPAH / = ACH Valve Aortic Replacement Hemisternotomy HRVLAOHST / = ACH Valve Aortic Replacement Primary Ablation RF HRVLAORF / = ACH Valve Aortic Replacement Primary Prosthesis HRVLAOPR / = ACH Valve Aortic Replacement Primary Tissue HRVLAOTS / = ACH Valve Aortic Replacement Redo Prosthesis HRVLAOPRRD / = ACH Valve Aortic Replacement Redo Tissue HRVLAOTSRD / = ACH Valve Aortic Replacement Thoracotomy HRVLAOTHO / = ACH Valve Aortic Replacement w Homograft HRVLAOHG / = ACH Valve Aortic Sparing Aortic Root Replacement HRVLASARR / = ACH Valve Mitral Clip Repair HRVLMICPR / = ACH Valve Mitral Commissurotomy HRVLMICOM / = ACH Valve Mitral Repair HRVLMIRP / = ACH Valve Mitral Repair/Replace+/-Tricuspid HRVLMIRRT / = ACH Valve Mitral Repair/Replace+/-Tricuspid Redo HRVLMIRRTR / = ACH Valve Mitral Replacement Minimally Invasive MIVS HRVLMRMI / = ACH Valve Mitral Replacement Primary Ablation RF HRVLMIRF / = ACH Valve Mitral Replacement Primary Prosthesis HRVLMIPR / = ACH Valve Mitral Replacement Primary Tissue HRVLMITS / = ACH Valve Mitral Replacement Redo Prosthesis HRVLMIPRRD / = Generated: 2021-04-06 11:02 Source: CAL ORIS medsurg Internal: proc_std_time 3 of 57 v.20191007 Disclaimer: This report is confidential. If received in error,
Load more

Recommended publications
  • Curriculum Vitae
    CURRICULUM VITAE STEVEN GITELIS, M.D. PERSONAL DATA: Professional Address: Midwest Orthopaedics at Rush 1611 West Harrison St. Suite 300 Chicago, Illinois 60612 (312) 563-2600 E-Mail: [email protected] CURRENT APPOINTMENTS/ACTIVITIES: Trustee Rush University Associate Dean Surgery Rush Medical College Associate Chief Medical Officer Rush University Chief of Surgery Rush University President Elect Medical Staff Rush University Director Cancer Research Rush University Surgical Services Executive Committee Rush University Executive Committee Rush University Patient Safety Officer Orthopedic Surgery Rush University Rush Credentialing Committee Rush Medical Quality Committee Rush Surgical Quality Committee Rush Bylaws Committee Rush University Committee on Committees Ends 2012 Editor Emeritus Rush Orthopaedic Journal Vice Chairman Department of Orthopedic Surgery Rush Medical College Treasurer Medical Staff Rush University Medical Center Ends 2010 Rush University Committee on Committees Rush University Psychiatry Chairman Search Committee 2010 Past President Rush Surgical Society Treasurer 20th Century Orthopedic Association Biological Implants Committee AAOS Ends 2013 Chairman Task Force Technology Oversight Committee AAOS Ends 2010 Director Rush Center for Limb Preservation Rush Medical College Professor of Orthopaedic Oncology (Endowed Chair) Past President, Musculoskeletal Tumor Society Director, Section of Orthopedic Oncology Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois Director, Bone and Tissue Bank of Gift of Hope
    [Show full text]
  • CORRECTION of DEFORMITIES of the JAW by Patrick Clarkson M.B.E., M.B., B.S., F.R.C.S
    CORRECTION OF DEFORMITIES OF THE JAW by Patrick Clarkson M.B.E., M.B., B.S., F.R.C.S. Casualty Surgeon, Guy's Hospital and Plastic Surgeon, Basingstoke Plastic;Ccntre. I. INTRODUCTION Degrees of Deformity and Pathology. Cooperation between Surgeon and Orthodontist. Surgical Treatment: Indication and Scope. Choice between radical surgery and " masking" operations. II. SURGICAL METHODS OF CORRECTION 1. Symmetrical Prognathism of the Mandible. 2. Asymmetrical Prognathism of the Mandible. 3. Symmetrical Recession of the Mandible. 4. Asymmetrical Recession of the Mandible. 5. The Jaw Deformities in Cleft Palate: Mandible and Maxilla. 6. Combined Jaw and Nasal Reductions. III. SUMMARY AND CONCLUSION I. INTRODUCTION A deformity of the jaw can be defined as any variation in these bones from the normal for the sex, age, and race of the patient; but only rela- tively gross variations come within the field of surgical repair. It is always possible by close examination to discover some degree of asymmetry in soft and bony tissues of the face, but the great majority of variations in facial skeleton, both symmetrical and unilateral, are scarcely noticeable to ordinary examination and require no treatment. Next in order of severity are a group of congenital origin which, given early and full ortho- dontic treatment, respond well without the need of surgery. This group includes a few of the early-cases of prognathism, of congenital open bite, and of recession of the jaw. Almost every case with these deformities can be improved by early orthodontic treatment. But all the more severe cases of prognathism, of recession, and the jaw deformities seen in patients with cleft palate, need surgical intervention if the correction is to be a complete one.
    [Show full text]
  • Gender Reassignment Surgery Policy Number: PG0311 ADVANTAGE | ELITE | HMO Last Review: 07/01/2021
    Gender Reassignment Surgery Policy Number: PG0311 ADVANTAGE | ELITE | HMO Last Review: 07/01/2021 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or guarantee regarding coverage or reimbursement/payment. Self-Insured group specific policy will supersede this general policy when group supplementary plan document or individual plan decision directs otherwise. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This medical policy is solely for guiding medical necessity and explaining correct procedure reporting used to assist in making coverage decisions and administering benefits. SCOPE X Professional X Facility DESCRIPTION Transgender is a broad term that can be used to describe people whose gender identity is different from the gender they were thought to be when they were born. Gender dysphoria (GD) or gender identity disorder is defined as evidence of a strong and persistent cross-gender identification, which is the desire to be, or the insistence that one is of the other gender. Persons with this disorder experience a sense of discomfort and inappropriateness regarding their anatomic or genetic sexual characteristics. Individuals with GD have persistent feelings of gender discomfort and inappropriateness of their anatomical sex, strong and ongoing cross-gender identification, and a desire to live and be accepted as a member of the opposite sex. Gender Dysphoria (GD) is defined by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition, DSM-5™ as a condition characterized by the "distress that may accompany the incongruence between one’s experienced or expressed gender and one’s assigned gender" also known as “natal gender”, which is the individual’s sex determined at birth.
    [Show full text]
  • Sarcoma of the Lower Limb: Reconstructive Surgeon's Perspective
    Published online: 2019-05-08 THIEME Review Article 55 Sarcoma of the Lower Limb: Reconstructive Surgeon’s Perspective Zhixue Lim1 Sophia A. Strike1 Mark E. Puhaindran1 1Department of Hand and Reconstructive Microsurgery, National Address for correspondence Zhixue Lim, MRCS (Edin), Department of University Hospital, Singapore, Singapore Hand and Reconstructive Microsurgery, National University Hospital, NUHS Tower Block, Level 11, 1E Kent Ridge Road, Singapore 119228, Singapore (e-mail: [email protected]). Indian J Plast Surg 2019;52:55–61 Abstract Management of sarcomas in the lower extremities have evolved from amputations to limb-preserving surgeries with evidence to support that they have equal overall Keywords survival, albeit with better functional outcome. The challenge of reconstruction lies ► sarcoma in providing a durable, functional, and aesthetically pleasing limb. However, limb- ► lower extremity preserving intention should not delay interventions that provide a survival benefit such ► reconstruction as chemotherapy and radiotherapy. The advent of radiotherapy and chemotherapy also ► vascularised bone has implications on wound healing and should be considered during the reconstruc- graft tive process. This article reviews the methodical approach, reconstructive strategies, ► soft tissue and considerations for the reconstructive surgeon with respect to the lower extremity reconstruction after sarcoma excision. who described a systematic approach to limb-preserving Introduction surgery in his article “Conservative surgery in the treatment Sarcomas are a diverse group of neoplasms that account of bone tumours,” where he shared his personal experience for approximately 1% of adult malignancies and 7 to 15% of in combining radiotherapy and surgical excision, with the 1 pediatric malignancies. The range of histological subtypes possibility of bone transplantation after resection of bone contributes to the varied prognoses.
    [Show full text]
  • Rotationplasty Offers Greater Functionality for Patients with Cancer
    Johns Hopkins Framework Orthopaedic Surgery NEWS FROM JOHNS HOPKINS MEDICINE Winter 2016 Rotationplasty Offers Greater Functionality for Patients with Cancer aya oberstein was diagnosed with osteosarcoma of Mthe distal femur in 2012, at age 9. After she completed chemotherapy, Maya’s treatment options Since Maya Oberstein’s initial 9.5-hour procedure, Carol Morris has been following were an above-knee up every six months to monitor her progress. amputation, limb salvage side. Cosmetically, if you’re sitting, it’s nice if the with an internal prosthesis or a knees are even.” Morris recalls her initial reluctance about the more unconventional approach: Post-op procedure. “I thought it was a physically challenging If you believe in yourself, rotationplasty. Carol Morris, thing to do to a child when prosthetics had made chief of Johns Hopkins’ tremendous advancements,” she says. “As I gained you can do anything.” more experience in the field, I began to appreciate —MAYA OBERSTEIN Orthopaedic Oncology Division, the limitations of internal prostheses and the is one of a select group of surgeons functionality rotationplasty could provide. For the in the United States who perform right parents and the right child, under the right set of circumstances, rotationplasty is a good operation. this alternative reconstructive It’s much more functional than an above-knee procedure. Morris counseled Maya amputation.” Traditional prostheses, especially growing and her family on the available protheses, are more restrictive than the modified options. “She was the first doctor transtibial prosthesis, limiting a patient’s ability to who asked me how I was feeling,” participate not only in sports, but in typical activities such as running, dancing and jumping.
    [Show full text]
  • MISSED? Metastatic Spinal Cord Compression NA Quraishi, C Esler ∗ BMJ 342 (7805), 1023-1025
    PUBLICATIONS (ABSTRACTS EXCLUDED) 2014: Metastatic spinal cord compression as a result of the unknown primary tumour. Quraishi NA, Ramoutar D, Sureshkumar D, Manoharan SR, Spencer A, Arealis G, Edwards KL, Boszczyk BM. Eur Spine J. 2014 Apr 2. Trans-oral approach for the management of a C2 neuroblastoma. Salem KM, Visser J, Quraishi NA. Eur Spine J. 2014 Feb 19. Calcified giant thoracic disc herniations: considerations and treatment strategies. Quraishi NA, Khurana A, Tsegaye MM, Boszczyk BM, Mehdian SM. Eur Spine J. 2014 Apr;23 Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Varga PP, Szövérfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, Chou D, Qurais NA, Reynolds JJ, Luzzati A, Williams R, Fehlings MG, Germscheid NM, Lazary A, Rhines LD. Eur Spine J. 2014 Dec 23. Expert's comment concerning Grand Rounds case entitled: "trans-oral approach for the management of a C2 neuroblastoma. (K. M. I. Salem, J. Visser, and N. A. Quraishi).Choi D. Eur Spine J. 2015 Jan;24(1):177-9. Diagnosis and treatment of a rectal-cutaneous fistula: a rare complication of coccygectomy. Behrbalk E, Uri O, Maxwell-Armstrong C, Quraishi NA. Eur Spine J. 2014 Nov 1. A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital. Bhosale UA, Quraishi N, Yegnanarayan R, Devasthale D. Niger Med J. 2014 Sep;55(5):417-22. An evidence-based medicine model for rare and often neglected neoplastic conditions. Fisher CG, Goldschlager T, Boriani S, Varga PP, Rhines LD, Fehlings MG, Luzzati A, Dekutoski MB, Reynolds JJ, Chou D, Berven SH, Williams RP, Quraishi NA, Bettegowda C, Gokaslan ZL.
    [Show full text]
  • Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 4.0 – October 2013
    Children’s OncologyLong-Term Group Long-Term Follow-UpFollow-Up Guidelines for Survivors of Childhood,Guidelines Adolescent, and Young Adult Cancer Version 4.0 – October 2013 for Survivors of Childhood, Adolescent, and Young Adult Cancers www.survivorshipguidelines.org Version 4.0 October 2013 Copyright 2013 © Children’s Oncology Group All rights reserved worldwide Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 4.0 – October 2013 www.survivorshipguidelines.org Copyright 2013 © Children’s Oncology Group All rights reserved worldwide Contents Content Outline vi Section # Page Gender Potential Late Effect Abstract vii 13 15 Female Gonadal dysfunction (ovarian) Disclaimer and Notice of Proprietary Rights viii 14 17 Acute myeloid leukemia; myelodysplasia Guidelines Panel of Experts x 15 18 Pulmonary fibrosis Guidelines Task Force Membership 2009–2012 xi 16 19 Cataracts Guidelines Health Link Authors xvi 17 20 Urinary tract toxicity Guidelines Health Link Reviewers xviii 18 21 Bladder malignancy Guidelines Development Task Force – Initial Versions xix 19 22 Renal toxicity Guidelines Reviewers – Initial Versions xx 20 23 Ototoxicity Introductory Material xxii 21 25 Peripheral sensory neuropathy; Introduction xxiii 22 26 Renal toxicity Explanation of Scoring xxviii (n/a) [Removed from v4: Dyslipidemia] Instructions for Use xxix 23 27 Neurocognitive deficits New to Version 4.0 xxxiv 24 29 Clinical leukoencephalopathy 25 31 No known late effects 26 32 Hepatic dysfunction; veno-occlusive disease
    [Show full text]
  • CMM-314: Hip Surgery-Arthroscopic and Open Procedures Version 1.0.2019
    CLINICAL GUIDELINES CMM-314: Hip Surgery-Arthroscopic and Open Procedures Version 1.0.2019 Clinical guidelines for medical necessity review of speech therapy services. © 2019 eviCore healthcare. All rights reserved. Comprehensive Musculoskeletal Management Guidelines V1.0.2019 CMM-314: Hip Surgery-Arthroscopic and Open Procedures CMM-314.1: Definitions 3 CMM-314.2: General Guidelines 4 CMM-314.3: Indications and Non-Indications 4 CMM-314.4 Experimental, Investigational, or Unproven 6 CMM-314.5: Procedure (CPT®) Codes 7 CMM-314.6: References 10 © 2019 eviCore healthcare. All rights reserved. Page 2 of 13 400 Buckwalter Place Boulevard, Bluffton, SC 29910 • (800) 918-8924 www.eviCore.com Comprehensive Musculoskeletal Management Guidelines V1.0.2019 CMM-314.1: Definitions Femoroacetabular Impingement (FAI) is an anatomical mismatch between the head of the femur and the acetabulum resulting in compression of the labrum or articular cartilage during flexion. The mismatch can arise from subtle morphologic alterations in the anatomy or orientation of the ball-and-socket components (for example, a bony prominence at the head-neck junction or acetabular over-coverage) with articular cartilage damage initially occurring from abutment of the femoral neck against the acetabular rim, typically at the anterosui per or aspect of the acetabulum. Although hip joints can possess the morphologic features of FAI without symptoms, FAI may become pathologic with repetitive movement and/or increased force on the hip joint. High-demand activities may also result in pathologic impingement in hips with normal morphology. s It ha been proposed that impingement with damage to the labrum and/or acetabulum is a causative factor in the development of hip osteoarthritis, and that as many as half of cases currently categorized as primary osteoarthritis may have an etiology of FAI.
    [Show full text]
  • Pathogenesis of Bone Erosions in Rheumatoid Arthritis: Not Only
    Rossini et al. J Rheum Dis Treat 2015, 1:2 ISSN: 2469-5726 Journal of Rheumatic Diseases and Treatment Review Article: Open Access Pathogenesis of Bone Erosions in Rheumatoid Arthritis: Not Only Inflammation Maurizio Rossini*, Angelo Fassio, Luca Idolazzi, Ombretta Viapiana, Elena Fracassi, Giovanni Adami, Maria Rosaria Povino, Maria Vitiello and Davide Gatti Department of Medicine, Rheumatology Unit, University of Verona, Italy *Corresponding author: Maurizio Rossini, Department of Medicine, Rheumatology Unit, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy, Tel: +390458126770, Fax: +39O458126881, E-mail: [email protected] patients has evidence of focal bone erosions [3]. This phenomenon Abstract is the result of many complex interactions from the cells and the It is a matter of fact that the inflammatory pathogenesis does not cytokines/chemokines system at the synovial and surrounding explain all the skeletal manifestations of Rheumatoid Arthritis tissues level, which culminates with bone destruction. In addition (RA), and the development of bone involvement is sometimes unconnected from the clinical scores of inflammation. On the to the articular crumbling, RA is also associated with a generalized basis of recent studies, we would like to make a point of the new bone loss with a higher prevalence of osteoporosis: RA patients have available evidence about the metabolic pathogenic component double the normal risk of undergoing a femoral fracture [4] and they of bone erosions. We assume that in this process an additional are 4 times more likely to have vertebral fractures [5,6]. Both erosions role could be played by metabolic factors, such as the parathyroid and systemic osteoporosis are related to the unbalance between hormone (PTH), DKK1 (the inhibitor of the Wnt/β catenin pathway) osteoblasts and osteoclasts activity [7,8].
    [Show full text]
  • Statistical Analysis Plan
    ~ GILEAU STATISTICAL ANALYSIS PLAN Study Title: A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety ofTenofovir Alafenamide (fAF) versus Tenofovir Disoproxil Fumarate (fDF)-containing Regimens in Subjects with Chmnic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant Name of Test Drug: Tenofovir Alafenamide (fAF) Study Number: GS-US-320-3912 Protocol Version (Date): Amendment 2 (28 March 2017) Analysis Type: Week 24 Analysis Plan Version: Version 1.0 Analysis Plan Date: 19 March 2018 ..._ ...... Analysis Plan Author(s): PD______ CONFIDENTIAL AND PROPRIETARY INFORMATION TAF GS-US-320-3912 Statistical Analysis Plan – Week 24 Analysis Version 1.0 TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................................................2 LIST OF IN-TEXT TABLES........................................................................................................................................4 LIST OF ABBREVIATIONS........................................................................................................................................5 1. INTRODUCTION ................................................................................................................................................8 1.1. Study Objectives ......................................................................................................................................8 1.2. Study Design ............................................................................................................................................9
    [Show full text]
  • CPT4 Code Descrip1on Charge Amount NICARDIPINE HCL 20MG
    CPT4 Code Descripon Charge Amount NICARDIPINE HCL 20MG/200ML PRE-MIXED IV $ 419.00 A9270GY TRAVATAN $ 354.00 BAYHEP B PFS $ 653.00 J1645 FRAGMIN 18000U $ 423.00 AMMONIA AROMATIC INH $ 4.00 A4340 CATH FOLEY COUDE LTX 5CC 22 FR $ 31.00 CLIP RESOLUTION $ 844.00 A4351 CATHETER URETHRAL BARDIA 14 FR $ 27.00 64832 REPAIR NERVE ADD ON $ 417.00 C1726 BALLOON HERCULES 15-16.5-18MM $ 663.00 C1726 DILATOR BAL CRE SGL USE FIXED $ 855.00 C1726 DILATOR BAL CRE SGL USE FIXED $ 855.00 C1726 DILATOR BAL CRE SGL USE FIXED $ 855.00 C1726 DILATOR CRE FIXED WIRE BALLOON $ 855.00 C1726 DILATOR COLONIC BAL CRE WIRE GU $ 986.00 27705 INCISION OF TIBIA $ 17,350.00 28270 RELEASE OF FOOT CONTRACTURE $ 8,186.00 28296 CORRECTION OF BUNION $ 8,186.00 28315 REMOVAL OF SESAMOID BONE $ 8,186.00 28405 TREATMENT OF HEEL FRACTURE $ 665.00 28725 FUSION OF FOOT BONES $ 31,327.00 29820 ARTHROSCOPY SHLDRR SYNOVEC PAR $ 17,350.00 29824 SHOULDER ARTHROSCOPY MUMFORD $ 8,186.00 29826 SHOULDER ARTHROSCOPY/SURGERY $ 1,440.00 29827 ARTHROSCOP ROTATOR CUFF REPR $ 17,350.00 29894 ANKLE ARTHROSCOPY/SURGERY $ 8,186.00 31254 REVISION OF ETHMOID SINUS $ 15,053.00 31295 SINUS ENDO W/BALLON DIL MAX $ 15,053.00 31297 SINUS ENDO W/BALLON DIL SPHENOID $ 15,053.00 36907 TRANSLUMINAL BALLOON ANGIOPLAST $ 235.00 38220 BONE MARROW ASPIRATION $ 4,172.00 46260 REMOVE IN/EX HEM GROUPS 2+ $ 7,166.00 47379 LAPAROSCOPE PROCEDURE LIVER $ 13,891.00 47600 REMOVAL OF GALLBLADDER $ 1,944.00 52235 CYSTOSCOPY AND TREATMENT $ 8,346.00 56501 DESTROY VULVA LESIONS SIM $ 4,854.00 58140 MYOMECTOMY ABDOM METHOD $ 2,156.00
    [Show full text]
  • Assurant Health and Welfare Plan 2019 Summary Plan Description
    Assurant Health and Welfare Plan 2019 Summary Plan Description October 8, 2018 New York, NY Main Table of Contents Getting to Know Your Assurant Benefits .....................................................3 Assurant Health and Welfare Plan ..............................................................4 Assurant Health Plan ...................................................................................14 Prescription Drug Coverage.........................................................................57 Employee Assistance Program .....................................................................64 Dental Plan ..................................................................................................67 Flexible Spending Accounts ........................................................................77 Life and Accident Insurance ........................................................................89 Disability Plan .............................................................................................106 Group Insurance ..........................................................................................120 Tuition Reimbursement Plan .......................................................................125 Commuter Benefits Program .......................................................................130 Severance Pay Plan .....................................................................................132 Plan Administration .....................................................................................137
    [Show full text]